Bioresorbable Drug-Eluting Magnesium-Alloy Scaffold for Treatment of Coronary Artery Disease

International Journal of Molecular Sciences

Carlos M. Campos¹  Takashi Muramatsu¹  Javaid Iqbal¹  Ya-Jun Zhang¹  Yoshinobu Onuma¹  Hector M. Garcia-Garcia¹  Michael Haude⁴  Pedro A. Lemos³  Boris Warnack² 

[1] Department of Interventional Cardiology, Erasmus University Medical Centre, Thoraxcenter, Rotterdam 3015 GD, The Netherlands; E-Mails:;BIOTRONIK AG, Bülach CH-8180, Switzerland; E-Mail:;Heart Institute (InCor), University of São Paulo Medical School, Sao Paulo 05403-000, Brazil; E-Mail:;Städtische Kliniken Neuss, Lukaskrankenhaus GmbH, Neuss 41464, Germany; E-Mail:

关键词: bioresorbable scaffold;    drug-eluting stent;    bioabsorbable;    biodegradable;    coronary artery disease;    magnesium;   

DOI  :  10.3390/ijms141224492

来源: mdpi

【 摘 要 】

The introduction of metallic drug-eluting stents has reduced the risk of restenosis and widened the indications of percutaneous coronary intervention in treatment of coronary artery disease. However, this medical device can induce hypersensitive reaction that interferes with the endothelialization and healing process resulting in late persistent or acquired malapposition of the permanent metallic implant. Delayed endotheliaization and malapposition may lead to late and very late stent thrombosis. Bioresorbable scaffolds (BRS) have been introduced to potentially overcome these limitations, as they provide temporary scaffolding and then disappear, liberating the treated vessel from its cage. Magnesium is an essential mineral needed for a variety of physiological functions in the human body and its bioresorbable alloy has the strength-to-weight ratio comparable with that of strong aluminum alloys and alloy steels. The aim of this review is to present the new developments in Magnesium BRS technology, to describe its clinical application and to discuss the future prospects of this innovative therapy.

【 授权许可】

CC BY   
© 2013 by the authors; licensee MDPI, Basel, Switzerland